SHERIDAN, WYOMING - April 14, 2026 - InspireMD, a medical technology company specializing in vascular disease treatment and embolic protection, is positioning its CGuard Prime carotid stent system as a clinical performance benchmark in carotid artery stenting, citing independently adjudicated trial data showing a 0.95% composite major adverse event rate at 30 days and 1.93% at one year-figures the company characterizes as the lowest of any pivotal carotid stenting study to date. The device's dual-layer MicroNet™ mesh architecture directly targets late embolization through stent struts, a failure mode associated with approximately two-thirds of major adverse events following carotid artery stenting procedures according to published vascular surgery research. CGuard Prime carries FDA clearance for use in high-surgical-risk patients requiring carotid revascularization and is marketed across U.S. and international markets.
Clinical Performance and Trial Data
The CGuard Prime outcome data originates from InspireMD's C-GUARDIANS Pivotal Trial, which recorded a 30-day Death, Stroke, or Myocardial Infarction (DSMI) rate of 0.95% and a one-year composite endpoint-DSMI through 30 days plus ipsilateral stroke from day 31 to 365-of 1.93% on a modified intent-to-treat Kaplan-Meier basis. InspireMD benchmarks these figures against a field of historical pivotal carotid stenting studies, including those published in the New England Journal of Medicine, Journal of Vascular Surgery, JACC Interventions, and Cardiovascular and Interventional Radiology, spanning 2004 through early 2025. Independent adjudication of endpoints underpins the company's comparative positioning, establishing a methodological basis for claims made against prior-generation single-layer stent systems.
Business Impact
For hospital systems, interventional cardiology units, and vascular surgery departments evaluating device procurement, the clinical dataset carries direct operational and purchasing relevance. The FDA indication targets a well-defined high-risk population: symptomatic patients with carotid stenosis of 50% or greater, or asymptomatic patients with stenosis of 80% or greater, with target vessel reference diameters between 6.4 mm and 9.0 mm. CGuard Prime is approved for use in conjunction with two named embolic protection systems-the Abbott Emboshield NAV6™ and the Medtronic Mo.Ma™ Ultra Proximal Cerebral Protection Device-defining the compatible accessory environment and downstream procurement requirements for any centre adopting the system. InspireMD's dual-market labeling strategy under both U.S. and international regulatory frameworks signals commercial intent across multiple jurisdictions.
Device Design and Technical Differentiation
CGuard Prime combines two proprietary design features. SmartFit™ Flexibility allows the stent to conform to varied carotid anatomies without requiring tapered configurations, reducing procedural complexity across a wide range of patient presentations. MicroNet™ Protection adds a non-metallic mesh layer with closed cells engineered to be the smallest in class, wrapping the stent body to prevent plaque prolapse and intercept embolic debris that would otherwise pass through conventional stent cell apertures. The design rationale addresses a finding from European vascular surgery literature that larger free cell areas in carotid stents correlate with elevated adverse outcome rates, providing a published mechanistic basis for the dual-layer approach.
Sector Context and Market Drivers
Stroke remains the third leading cause of death globally according to WHO 2024 data, sustaining long-term demand for effective carotid intervention devices. Carotid artery stenting competes with carotid endarterectomy as a revascularization modality in high-surgical-risk patients, and device-level outcome differentiation is increasingly central to clinical guideline development and institutional procurement decisions. InspireMD's evidence strategy-anchored in a named pivotal trial with independently adjudicated endpoints and supported by physician testimonials from hospital centres in Italy and Spain-follows an established pathway for building procedural credibility in high-acuity cardiovascular intervention markets. The breadth of referenced comparative studies, spanning over two decades of pivotal CAS trials, positions CGuard Prime within the full historical context of the category rather than against a narrow subset of competitors.
Key facts:
- C-GUARDIANS Pivotal Trial recorded 0.95% DSMI at 30 days for CGuard Prime
- One-year composite endpoint (DSMI plus ipsilateral stroke, day 31-365) was 1.93% by modified ITT Kaplan-Meier analysis
- Indicated for high-surgical-risk patients with symptomatic ≥50% or asymptomatic ≥80% carotid stenosis; vessel diameter 6.4-9.0 mm
- Approved for use with Abbott Emboshield NAV6™ or Medtronic Mo.Ma™ Ultra embolic protection systems
- Stroke is the third leading cause of death globally, per WHO 2024